Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 1
2016 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.
Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Kandzari DE, et al. Eur Heart J. 2015 Jan 21;36(4):219-27. doi: 10.1093/eurheartj/ehu441. Epub 2014 Nov 16. Eur Heart J. 2015. PMID: 25400162 Free PMC article. Clinical Trial.
AIMS: The SYMPLICITY HTN-3 randomized, blinded, sham-controlled trial confirmed the safety of renal denervation (RDN), but did not meet its primary efficacy endpoint. ...CONCLUSIONS: Post hoc analyses, although derived from limited patient cohorts, rev …
AIMS: The SYMPLICITY HTN-3 randomized, blinded, sham-controlled trial confirmed the safety of renal denervation …
Renal Denervation: Is It Ready for Prime Time?
Lauder L, Wolf MA, Scholz SS, Hohl M, Mahfoud F, Böhm M. Lauder L, et al. Curr Cardiol Rep. 2019 Jul 5;21(8):80. doi: 10.1007/s11886-019-1164-2. Curr Cardiol Rep. 2019. PMID: 31278490 Review.
This review provides an up to date overview of renal denervation trials and an outlook on what to expect in the future. RECENT FINDINGS: After the sham-controlled SYMPLICITY HTN-3 trial dampened the euphoria following early renal denervation …
This review provides an up to date overview of renal denervation trials and an outlook on what to expect in the future. RECENT FINDIN …
Catheter-based renal artery denervation: facts and expectations.
Verdecchia P, Cavallini C, Sclafani R, Santucci A, Notaristefano F, Zingarini G, Colombo GA, Angeli F. Verdecchia P, et al. Eur J Intern Med. 2023 Nov;117:66-77. doi: 10.1016/j.ejim.2023.07.041. Epub 2023 Aug 4. Eur J Intern Med. 2023. PMID: 37544846 Review.
Catheter-based renal artery denervation (RAD) is entering a new era. After the disappointing results of SYMPLICITY-HTN 3 trial in year 2014, several technical and methodological advancements led to execution of important SHAM-controlled randomized t …
Catheter-based renal artery denervation (RAD) is entering a new era. After the disappointing results of SYMPLICITY-HTN 3 …
Renal denervation: a new therapeutic approach for resistant hypertension.
Cao L, Fu Q, Wang B, Li Z. Cao L, et al. Chin Med J (Engl). 2014;127(18):3302-8. Chin Med J (Engl). 2014. PMID: 25266531 Review.
Although several studies have shown the efficacy and safety of renal denervation in the treatment of resistant hypertension and the potential benefit of the procedure in other diseases, Symplicity HTN 3 study, the most rigorous clinical trial of …
Although several studies have shown the efficacy and safety of renal denervation in the treatment of resistant hypertension and the potentia …
Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges.
Persu A, Kjeldsen S, Staessen JA, Azizi M. Persu A, et al. Curr Hypertens Rep. 2016 Jan;18(1):6. doi: 10.1007/s11906-015-0610-9. Curr Hypertens Rep. 2016. PMID: 26739586 Review.
A sudden shift from overoptimistic views to radical scepticism occurred later, when the large US randomized sham-controlled trial Symplicity HTN-3 failed to meet its primary blood pressure lowering efficacy endpoint. Experts are divided o …
A sudden shift from overoptimistic views to radical scepticism occurred later, when the large US randomized sham-controlled trial …